TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

25 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

22 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Aug 2022 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2022 Financial Results

04 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Updates on its Development Programs

03 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2022 Financial Results

28 Jul 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2022 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Jun 2022 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

02 Jun 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

17 May 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 May 2022 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2022 Financial Results

05 May 2022 16:01:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

03 May 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2022 Financial Results

28 Apr 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

20 Apr 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Apr 2022 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022

06 Apr 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

21 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Mar 2022 17:00:00 By Nasdaq GlobeNewswire